ProCE Banner Activity

Phase III NEOTORCH: Interim EFS Analysis of Perioperative Toripalimab + Platinum-Doublet CT vs Platinum-Doublet CT in Resectable Stage II/III NSCLC

Conference Coverage
Slideset

Perioperative toripalimab + CT significantly improved event-free survival compared with perioperative CT alone in patients with resectable stage III NSCLC.

Released: June 06, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme Corp., and Novocure.

AstraZeneca

Daiichi Sankyo

Merck Sharp & Dohme Corp.

Novocure